Editas Capital Lease Obligations from 2010 to 2024
| EDIT Stock | USD 2.20 0.01 0.45% |
Capital Lease Obligations | First Reported 2016-03-31 | Previous Quarter 38.7 M | Current Value 38.5 M | Quarterly Volatility 7.2 M |
Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 3 M or Selling General Administrative of 57.9 M, as well as many indicators such as Price To Sales Ratio of 9.36, Dividend Yield of 0.0 or PTB Ratio of 2.31. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.
Editas | Capital Lease Obligations |
Latest Editas Medicine's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Editas Medicine over the last few years. Editas Medicine capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Editas Medicine asset purchases. For example, Editas Medicine can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Editas Medicine control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Editas Medicine's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Editas Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 33,984,083 | |
| Geometric Mean | 33,716,985 | |
| Coefficient Of Variation | 12.81 | |
| Mean Deviation | 2,997,122 | |
| Median | 35,096,000 | |
| Standard Deviation | 4,354,198 | |
| Sample Variance | 19T | |
| Range | 17.8M | |
| R-Value | (0.06) | |
| Mean Square Error | 20.3T | |
| R-Squared | 0 | |
| Significance | 0.83 | |
| Slope | (57,462) | |
| Total Sum of Squares | 265.4T |
Editas Capital Lease Obligations History
About Editas Medicine Financial Statements
Editas Medicine shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 36.5 M | 36.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.